Laser and Light-Sensitive drug shrink lung tumors in early trial

NCT ID NCT03735095

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a treatment called photodynamic therapy for people with advanced lung cancer that blocks airways. Patients received a light-sensitive drug followed by a laser to activate it inside the tumor. The goal was to see if the treatment is safe and can shrink tumors to ease symptoms. Nineteen adults with lung cancer took part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Porfimer sodium (a light-sensitive drug)
What this could lead to
If successful, this approach could offer a new way to shrink airway-blocking tumors and improve breathing in people with advanced lung cancer.
What could go wrong
This is an early-phase trial with only 19 participants, so results may not apply to everyone. The treatment involves a drug that makes skin and eyes sensitive to light, and there is a risk of serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.